Sweetening the pot: Adding glycosylation to the biomarker discovery equation

Clinical Chemistry

Volumn 56, Issue 2, 2010, Pages 223-236

  Drake, Penelope M ^a   Cho, Wonryeon ^b   Li, Bensheng ^c   Prakobphol, Akraporn ^a   Johansen, Eric ^a   Anderson, N Leigh ^d   Regnier, Fred E ^b   Gibson, Bradford W ^c   Fisher, Susan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PURDUE UNIVERSITY   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d The Plasma Proteome Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; LECTIN; MATRIX METALLOPROTEINASE; OLIGOSACCHARIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER THERAPY; DISEASE COURSE; GEL ELECTROPHORESIS; GENE OVEREXPRESSION; GLYCOSYLATION; HUMAN; MONITORING; REVIEW; SENSITIVITY AND SPECIFICITY;

GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LECTINS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 75849140063     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.136333     Document Type: Review

References (155)

1. Meezan E, Wu HC, Black PH, Robbins PW. Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by Sephadex chromatography. Biochemistry 1969;8:2518-24.
2. Backstrom M, Thomsson KA, Karlsson H, Hansson GC. Sensitive liquid chromatographyelectrospray mass spectrometry allows for the analysis of the O-glycosylation of immunoprecipitated proteins from cells or tissues: application to MUC1 glycosylation in cancer. J Proteome Res 2009;8:538-45.
3. Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, et al. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics 2009;25:251-7.
4. Goldberg D, Bern M, Parry S, Sutton-Smith M, Panico M, Morris HR, Dell A. Automated N-glycopeptide identification using a combination of single- and tandem-MS. J Proteome Res 2007;6:3995-4005.
5. Harvey DJ. Structural determination of N-linked glycans by matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. Proteomics 2005;5:1774-86.
6. Laughlin ST, Bertozzi CR. Imaging the glycome. Proc Natl Acad Sci U S A 2009;106:12-7.
7. North SJ, Hitchen PG, Haslam SM, Dell A. Mass spectrometry in the analysis of N-linked and O-linked glycans. Curr Opin Struct Biol 2009;19:498-506.
8. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 2008;376:1-12.
9. Tang H, Mechref Y, Novotny MV. Automated interpretation of MS/MS spectra of oligosaccharides. Bioinformatics 2005;21 Suppl 1:i431-9.
10. Werz DB, Seeberger PH. Carbohydrates as the next frontier in pharmaceutical research. Chemistry 2005;11:3194 -206.
11. Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009;6:123-34.
12. Barrabes S, Pages-Pons L, Radcliffe CM, Tabares G, Fort E, Royle L, et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 2007;17:388-400.
13. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2009;8:791-8.
14. Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res 2009;8:613-9.
15. Misonou Y, Shida K, Korekane H, Seki Y, Noura S, Ohue M, Miyamoto Y. Comprehensive clinicoglycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. J Proteome Res 2009;8:2990-3005.
16. Mizuochi T, Nishimura R, Derappe C, Taniguchi T, Hamamoto T, Mochizuki M, Kobata A. Structures of the asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma: appearance of triantennary sugar chains and unique biantennary sugar chains. J Biol Chem 1983;258:14126-9.
17. Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004;64:1821-7.
18. Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004;14:671-9.
19. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003;13:457-70.
20. Taylor AD, Hancock WS, Hincapie M, Taniguchi N, Hanash SM. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med 2009;1:57.
21. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
22. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005; 58:308-12.
23. Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark 2008;4:35-42.
24. van Gisbergen KP, Aarnoudse CA, Meijer GA, Geijtenbeek TB, van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res 2005;65:5935-44.
25. Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19-27.
26. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982;257:14365-9.
27. Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20:362-71.
28. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, Orntoft TF. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61.
29. Prakobphol A, Boren T, Ma W, Zhixiang P, Fisher SJ. Highly glycosylated human salivary molecules present oligosaccharides that mediate adhesion of leukocytes and Helicobacter pylori. Biochemistry 2005;44:2216-24.
30. Serpa J, Almeida R, Oliveira C, Silva FS, Silva E, Reis C, et al. Lewis enzyme (alpha1-3/4 fucosyl-transferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. J Hum Genet 2003;48:183-9.
31. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998;58:512-8.
32. Brooks SA, Leathem AJ. Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour. Lancet 1991;338:71-4.
33. Fenlon S, Ellis IO, Bell J, Todd JH, Elston CW, Blamey RW. Helix pomatia and Ulex europeus lectin binding in human breast carcinoma. J Pathol 1987;152:169-76.
34. Fukutomi T, Itabashi M, Tsugane S, Yamamoto H, Nanasawa T, Hirota T. Prognostic contributions of Helix pomatia and carcinoembryonic antigen staining using histochemical techniques in breast carcinomas. Jpn J Clin Oncol 1989;19:127-34.
35. Kakeji Y, Maehara Y, Tsujitani S, Baba H, Ohno S, Watanabe A, Sugimachi K. Helix pomatia agglutinin binding activity and lymph node metastasis in patients with gastric cancer. Semin Surg Oncol 1994;10:130-4.
36. Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E, Huland H. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002;168:470-4.
37. Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, Jibiki M, et al. Expression of Lewis(a), sialyl Lewis(a), Lewis(x) and sialyl Lewis(x) antigens as prognostic factors in patients with colorectal cancer. Can J Gastroenterol 2000;14:753-60.
38. Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H. Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 1993;71:3044-53.
39. Ogawa J, Sano A, Inoue H, Koide S. Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann Thorac Surg 1995;59:412-5.
40. Ohyama C. Glycosylation in bladder cancer. Int J Clin Oncol 2008;13:308-13.
41. Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998;159:389 -92; discussion 93.
42. Steplewska-Mazur K, Gabriel A, Zajecki W, Wylezol M, Gluck M. Breast cancer progression and expression of blood group-related tumor-associated antigens. Hybridoma 2000;19:129-33.
43. Tauchi K, Kakudo K, Machimura T, Makuuchi H, Mitomi T. Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer 1991;67: 3042-50.
44. Bao X, Kobayashi M, Hatakeyama S, Angata K, Gullberg D, Nakayama J, et al. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci U S A 2009;106:12109-14.
45. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A 2005;102: 4572-7.
46. Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama C, Khoo KH, et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J Biol Chem 2009;284:17157-69.
47. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000;6:306-12.
48. Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, Roth J. Prognostic value of beta1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res 1998;58: 5559-64.
49. Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 1999;9:1307-11.
50. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. STn and prognosis in breast cancer. Oncology 2001;61:299-305.
51. Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 2006;281:3586 -94.
52. Chiricolo M, Malagolini N, Bonfiglioli S, Dall'Olio F. Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948. Glycobiology 2006;16:146-54.
53. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725-9.
54. Kudo T, Ikehara Y, Togayachi A, Morozumi K, Watanabe M, Nakamura M, et al. Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab Invest 1998;78:797-811.
55. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98:621-8.
56. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008;8:929-41.
57. Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res 2008;10:205.
58. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 2009;15:RA32-40.
59. Andre S, Kozar T, Kojima S, Unverzagt C, Gabius HJ. From structural to functional glycomics: core substitutions as molecular switches for shape and lectin affinity of N-glycans. Biol Chem 2009; 390:557-65.
60. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
61. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Gronholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta 2009;1790:431-44.
62. Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J 2004;21:9-15.
63. Isaji T, Sato Y, Fukuda T, Gu J. N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1. J Biol Chem 2009;284:12207-16.
64. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by upregulating cell motility. Cancer Res 2005;65: 4645-52.
65. Hedlund M, Ng E, Varki A, Varki NM. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68:388 -94.
66. Ahmad N, Gabius HJ, Andre S, Kaltner H, Sabesan S, Roy R, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 2004;279:10841-7.
67. Lagana A, Goetz JG, Cheung P, Raz A, Dennis JW, Nabi IR. Galectin binding to MGAT5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 2006; 26:3181-93.
68. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science (Wash DC) 2004; 306:120-4.
69. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
70. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 2008;25:335- 44.
71. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009;9: 285-93.
72. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Ann Rev Immunol 2004;22:129-56.
73. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev 2008; 27:19-30.
74. Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 2008;283: 15647-55.
75. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001;98: 3352-7.
76. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A 2002; 99:2193-8.
77. Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996; 183:581-7.
78. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteom 2006;5:1957-67.
79. Taniguchi N, Hancock W, Lubman DM, Rudd PM. The second golden age of glycomics: from functional glycomics to clinical applications. J Proteome Res 2009;8:425-6.
80. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008;54:1608-16.
81. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteom 2008;7:1963-73.
82. Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B, et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 2009;8:595-602.
83. Kullolli M, Hancock WS, Hincapie M. Preparation of a high-performance multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the analysis of human plasma glycoproteins. J Sep Sci 2008;31:2733-9.
84. Jung K, Cho W, Regnier FE. Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. J Proteome Res 2009;8: 643-50.
85. Yang N, Li DF, Feng L, Xiang Y, Liu W, Sun H, Wang DC. Structural basis for the tumor cell apoptosis-inducing activity of an antitumor lectin from the edible mushroom Agrocybe aegerita. J Mol Biol 2009;387:694-705.
86. Maley F, Trimble RB, Tarentino AL, Plummer TH Jr. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 1989;180:195-204.
87. Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, et al. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol 2003;21:667-72.
88. Xiong L, Andrews D, Regnier F. Comparative proteomics of glycoproteins based on lectin selection and isotope coding. J Proteome Res 2003;2:618-25.
89. Calvano CD, Zambonin CG, Jensen ON. Assessment of lectin and HILIC based enrichment protocols for characterization of serum glycoproteins by mass spectrometry. J Proteomics 2008; 71:304-17.
90. Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007;7:4292-302.
91. Plavina T, Wakshull E, Hancock WS, Hincapie M. Combination of abundant protein depletion and multi-lectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J Proteome Res 2007;6:662-71.
92. Yang Z, Harris LE, Palmer-Toy DE, Hancock WS. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin Chem 2006;52:1897-905.
93. Cho W, Jung K, Regnier FE. Use of glycan targeting antibodies to identify cancer-associated glycoproteins in plasma of breast cancer patients. Anal Chem 2008;80:5286-92.
94. Yang Z, Hancock WS. Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J Chromatogr A 2004;1053:79-88.
95. Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, et al. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. J Proteome Res 2008;7: 1470-80.
96. Lee YC, Block G, Chen H, Folch-Puy E, Foronjy R, Jalili R, et al. One-step isolation of plasma membrane proteins using magnetic beads with immobilized concanavalin A. Protein Expr Purif 2008;62:223-9.
97. Bond MR, Kohler JJ. Chemical methods for glycoprotein discovery. Curr Opin Chem Biol 2007; 11:52-8.
98. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-6.
99. Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H. Solid-phase extraction of N-linked glycopeptides. Nat Protoc 2007;2:334 -9.
100. Sun B, Ranish JA, Utleg AG, White JT, Yan X, Lin B, Hood L. Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics. Mol Cell Proteomics 2007;6:141-9.
101. Sparbier K, Koch S, Kessler I, Wenzel T, Kostrzewa M. Selective isolation of glycoproteins and glycopeptides for MALDI-TOF MS detection supported by magnetic particles. J Biomol Tech 2005;16:407-13.
102. Sparbier K, Asperger A, Resemann A, Kessler I, Koch S, Wenzel T, et al. Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/TOF analysis with automated glycopeptide detection. J Biomol Tech 2007;18:252-8.
103. Zhang H, Loriaux P, Eng J, Campbell D, Keller A, Moss P, et al. UniPep - a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol 2006;7:R73.
104. Laughlin ST, Bertozzi CR. Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation. Nat Protoc 2007;2:2930-44.
105. Goetz JA, Mechref Y, Kang P, Jeng MH, Novotny MV. Glycomic profiling of invasive and noninvasive breast cancer cells. Glycoconj J 2009; 26:117-31.
106. Yamada K, Kinoshita M, Hayakawa T, Nakaya S, Kakehi K. Comparative studies on the structural features of O-glycans between leukemia and epithelial cell lines. J Proteome Res 2009;8:521-37.
107. Li B, An HJ, Kirmiz C, Lebrilla CB, Lam KS, Miyamoto S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res 2008;7: 3776-88.
108. Bereman MS, Williams TI, Muddiman DC. Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem 2009;81:1130-6.
109. de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, et al. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers 2008;25:243-58.
110. Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteom 2007;6:43-55.
111. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
112. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, Domon B. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteom 2007;6:1809 -17.
113. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27: 633-41.
114. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004;3:235- 44.
115. Ahn YH, Lee JY, Kim YS, Ko JH, Yoo JS. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009;8:4216-24.
116. Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteom 2009;8: 995-1005.
117. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007;4:437-44.
118. Wu YM, Nowack D, Omenn G, Haab B. Mucin glycosylation is altered by pro-inflammatory signaling signaling in pancreatic-cancer cells. J Proteome Res 2009;8:1876-86.
119. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177- 85.
120. Presant CA, Kornfeld S. Characterization of the cell surface receptor for the Agaricus bisporus hemagglutinin. J Biol Chem 1972;247:6937-45.
121. Sueyoshi S, Yamamoto K, Osawa T. Carbohydrate binding specificity of a beetle (Allomyrina dichotoma) lectin. J Biochem 1988;103:894-9.
122. Ahmed H, Chatterjee BP. Further characterization and immunochemical studies on the carbohydrate specificity of jackfruit (Artocarpus integrifolia) lectin. J Biol Chem 1989;264:9365-72.
123. Kaladas PM, Kabat EA, Iglesias JL, Lis H, Sharon N. Immunochemical studies on the combining site of the D-galactose/N-acetyl- D-galactosamine specific lectin from Erythrina cristagalli seeds. Arch Biochem Biophys 1982;217:624-37.
124. Swamy MJ, Gupta D, Mahanta SK, Surolia A. Further characterization of the saccharide specificity of peanut (Arachis hypogaea) agglutinin. Carbohydr Res 1991;213:59-67.
125. Torres BV, McCrumb DK, Smith DF. Glycolipid-lectin interactions: reactivity of lectins from Helix pomatia, Wisteria floribunda, and Dolichos biflorus with glycolipids containing N-acetylgalactosamine. Arch Biochem Biophys 1988;262:1-11.
126. Piller V, Piller F, Cartron JP. Comparison of the carbohydrate-binding specificities of seven N-acetyl-D-galactosamine-recognizing lectins. Eur J Biochem 1990;191:461-6.
127. Roberts DD, Goldstein IJ. Reexamination of the carbohydrate binding stoichiometry of lima bean lectin. Arch Biochem Biophys 1984;230: 316-20.
128. Shen ZM, Shi WX, Sun C, Yang JT. Conformation and activity of mannose- and N-acetyl-galactosamine-specific lectins from Vicia villosa seeds. Biochimie 1993;75:949-54.
129. Crowley JF, Goldstein IJ, Arnarp J, Lonngren J. Carbohydrate binding studies on the lectin from Datura stramonium seeds. Arch Biochem Biophys 1984;231:524-33.
130. Wood C, Kabat EA, Ebisu S, Goldstein IJ. An immunochemical study of the combining sites of the second lectin isolated from Bandeiraea simplicifolia (BS II). Ann Immunol (Paris) 1978;129: 143-58.
131. Nachbar MS, Oppenheim JD, Thomas JO. Lectins in the U.S. diet: isolation and characterization of a lectin from the tomato (Lycopersicon esculentum). J Biol Chem 1980;255:2056-61.
132. Allen AK, Neuberger A, Sharon N. The purification, composition and specificity of wheat-germ agglutinin. Biochem J 1973;131:155-62.
133. Peters BP, Ebisu S, Goldstein IJ, Flashner M. Interaction of wheat germ agglutinin with sialic acid. Biochemistry 1979;18:5505-11.
134. Yamamoto K, Tsuji T, Matsumoto I, Osawa T. Structural requirements for the binding of oligosaccharides and glycopeptides to immobilized wheat germ agglutinin. Biochemistry 1981;20: 5894-9.
135. Debray H, Decout D, Strecker G, Spik G, Montreuil J. Specificity of twelve lectins towards oligosaccharides and glycopeptides related to N-glycosylproteins. Eur J Biochem 1981;117:41-55.
136. Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M, Peeters B, Peumans WJ. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem 1987;262:1596-601.
137. Kornfeld K, Reitman ML, Kornfeld R. The carbohydrate-binding specificity of pea and lentil lectins. Fucose is an important determinant. J Biol Chem 1981;256:6633-40.
138. Debray H, Montreuil J. Aleuria aurantia agglutinin. A new isolation procedure and further study of its specificity towards various glycopeptides and oligosaccharides. Carbohydr Res 1989; 185:15-26.
139. Horejsi V, Ticha M, Kocourek J. Studies on lectins. XXXII. Application of affinity electrophoresis to the study of the interaction of lectins and their derivatives with sugars. Biochim Biophys Acta 1977;499:301-8.
140. Pereira ME, Kabat EA. Specificity of purified hemagglutinin (lectin) from Lotus tetragonolobus. Biochemistry 1974;13:3184-92.
141. Sughii S, Kabat EA, Baer HH. Further immunochemical studies on the combining sites of Lotus tetragonolobus and Ulex europaeus I and II lectins. Carbohydr Res 1982;99:99-101.
142. Ravindranath MH, Higa HH, Cooper EL, Paulson JC. Purification and characterization of an O-acetylsialic acid-specific lectin from a marine crab Cancer antennarius. J Biol Chem 1985;260: 8850-6.
143. Wang WC, Cummings RD. The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 1988;263:4576-85.
144. Kolberg J, Michaelsen TE, Sletten K. Properties of a lectin purified from the seeds of Cicer arietinum. Hoppe Seylers Z Physiol Chem 1983; 364:655-64.
145. Petryniak J, Goldstein IJ. Evonymus europaea lectin. Methods Enzymol 1987;138:552-61.
146. Cummings RD, Kornfeld S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J Biol Chem 1982;257:11230-4.
147. Nemec M, Drimalova D, Horejsi V, Vanak J, Bartek J, Viklicky V. Murine monoclonal antibodies to human A erythrocytes: differential reactivity with N-acetyl-D-galactosamine. Vox Sang 1987;52:125-8.
148. Vanak J, Drimalova D, Smyslova O, Nemec M, Viklicky V, Wisniewski K. Detection of blood group A antigen expression in human colon cancer using monoclonal antibodies with different specificities. Neoplasma 1989;36:479-88.
149. Nystrom K, Grahn A, Lindh M, Brytting M, Mandel U, Larson G, Olofsson S. Virus-induced transcriptional activation of host FUT genes associated with neo-expression of Ley in cytomegalovirus-infected and sialyl-Lex in varicella-zoster virus-infected diploid human cells. Glycobiology 2007;17:355-66.
150. Rye PD, Bovin NV, Vlasova EV, Molodyk AA, Baryshnikov A, Kreutz FT, et al. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreux, Switzerland, September 19-24, 1997. Tumour Biol 1998;19: 390-420.
151. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008;112:3661-70.
152. Lund-Johansen F, Olweus J, Horejsi V, Skubitz KM, Thompson JS, Vilella R, Symington FW. Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, CDw17, and CDw65). J Immunol 1992;148:3221-9.
153. Mitsuoka C, Kawakami-Kimura N, Kasugai-Sawada M, Hiraiwa N, Toda K, Ishida H, et al. Sulfated sialyl Lewis X, the putative L-selectin ligand, detected on endothelial cells of high endothelial venules by a distinct set of antisialyl Lewis X antibodies. Biochem Biophys Res Commun 1997;230:546 -51.
154. Yeh CY, Lin CN, Chang CF, Lin CH, Lien HT, Chen JY, Chia JS. C-terminal repeats of Clostridium difficile toxin A induce production of chemokine and adhesion molecules in endothelial cells and promote migration of leukocytes. Infect Immun 2008;76:1170-8.
155. Hemmerich S, Butcher EC, Rosen SD. Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody. J Exp Med 1994;180:2219-26.